<DOC>
	<DOCNO>NCT01881217</DOCNO>
	<brief_summary>An open-label , non-randomized , Phase I dose-escalation study design assess safety , tolerability , pharmacokinetics ( PK ) /pharmacodynamics ( PD ) tumor response profile BAY1179470 subject advanced , refractory solid tumor</brief_summary>
	<brief_title>First-in-man Dose Escalation Study BAY1179470 Patients With Advanced , Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects advance , histologically cytologically confirm solid tumor refractory standard therapy standard therapy available subject actively refuse treatment would regard standard Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 life expectancy least 3 month At least moderate FGFR2 expression tumor tissue archival sample confirm : subject additional cohort History severe allergic reaction monoclonal antibody therapy Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mmHg , despite optimal medical management Any condition unstable could jeopardize safety subject / compliance study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Advanced , refractory solid tumor</keyword>
	<keyword>FGFR2</keyword>
</DOC>